Search

Your search keyword '"Di Sapio, A."' showing total 502 results

Search Constraints

Start Over You searched for: Author "Di Sapio, A." Remove constraint Author: "Di Sapio, A."
502 results on '"Di Sapio, A."'

Search Results

2. Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA)

3. Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project

4. ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis

5. Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project

6. A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis

7. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

8. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

9. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

10. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

12. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

14. Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

15. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

16. Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study

17. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study

18. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

19. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

20. A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis.

21. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy

22. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

23. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

24. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

25. Screening for Fabry disease in unknown origin axonal polyneuropathy: to do or not to do, this is the question!

27. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

28. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

30. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

33. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

34. Signs and symptoms of COVID-19 in patients with multiple sclerosis

35. Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology (Nature Genetics, (2021), 53, 12, (1636-1648), 10.1038/s41588-021-00973-1)

36. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

37. The effect of air pollution on COVID‐19 severity in a sample of patients with multiple sclerosis

38. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

41. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

42. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

43. Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study

44. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register

45. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

46. Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration

47. Cladribine vs other drugs in MS: Merging randomized trial with real-life data

48. Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

49. Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology

50. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

Catalog

Books, media, physical & digital resources